sr141716 has been researched along with Colonic Neoplasms in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Bifulco, G; Bifulco, M; Bizzarro, V; Feoli, A; Fiore, D; Franceschelli, S; Gazzerro, P; Laezza, C; Lauro, G; Piscopo, C; Proto, MC; Sbardella, G; Tosco, A | 1 |
| Bifulco, M; Caraglia, M; Caruso, MG; Gazzerro, P; Laezza, C; Malfitano, AM; Messa, C; Misso, G; Notarnicola, M; Pisanti, S; Proto, MC; Santoro, A | 1 |
2 other study(ies) available for sr141716 and Colonic Neoplasms
| Article | Year |
|---|---|
Inhibition of Wnt/β-Catenin pathway and Histone acetyltransferase activity by Rimonabant: a therapeutic target for colon cancer.
Topics: Animals; Cannabinoid Receptor Antagonists; Cell Line, Tumor; Colonic Neoplasms; Colorectal Neoplasms; Disease Models, Animal; Female; Heterografts; Histone Acetyltransferases; Humans; Mice, SCID; Models, Biological; Neoplasm Transplantation; Rimonabant; Treatment Outcome; Wnt Signaling Pathway | 2017 |
Synergistic inhibition of human colon cancer cell growth by the cannabinoid CB1 receptor antagonist rimonabant and oxaliplatin.
Topics: Antineoplastic Combined Chemotherapy Protocols; Cell Line, Tumor; Cell Proliferation; Colonic Neoplasms; Dose-Response Relationship, Drug; Drug Screening Assays, Antitumor; Drug Synergism; Humans; Organoplatinum Compounds; Oxaliplatin; Piperidines; Pyrazoles; Receptor, Cannabinoid, CB1; Rimonabant; Time Factors | 2010 |